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Abstract
Background: The recruitment of vascular stromal and endothelial cells is an early event occurring during cancer
cell growth at premetastatic niches, but how the microenvironment created by the initial three-dimensional (3D)
growth of cancer cells affects their angiogenesis-stimulating potential is unclear.
Methods: The proangiogenic profile of CT26 murine colorectal carcinoma cells was studied in seven-day
cultured 3D-spheroids of <300 μm in diameter, produced by the hanging-drop method to mimic the
microenvironment of avascular micrometastases prior to hypoxia occurrence.
Results: Spheroid-derived CT26 cells increased vascular endothelial growth factor (VEGF) secretion by 70%,
which in turn increased the in vitro migration of primary cultured hepatic sinusoidal endothelium (HSE) cells by 2-
fold. More importantly, spheroid-derived CT26 cells increased lymphocyte function associated antigen (LFA)-1-
expressing cell fraction by 3-fold; and soluble intercellular adhesion molecule (ICAM)-1, given to spheroid-
cultured CT26 cells, further increased VEGF secretion by 90%, via cyclooxygenase (COX)-2-dependent
mechanism. Consistent with these findings, CT26 cancer cells significantly increased LFA-1 expression in non-
hypoxic avascular micrometastases at their earliest inception within hepatic lobules in vivo; and angiogenesis also
markedly increased in both subcutaneous tumors and hepatic metastases produced by spheroid-derived CT26
cells.
Conclusion: 3D-growth per se enriched the proangiogenic phenotype of cancer cells growing as multicellular
spheroids or as subclinical hepatic micrometastases. The contribution of integrin LFA-1 to VEGF secretion via
COX-2 was a micro environmental-related mechanism leading to the pro-angiogenic activation of soluble ICAM-
1-activated colorectal carcinoma cells. This mechanism may represent a new target for specific therapeutic
strategies designed to block colorectal cancer cell growth at a subclinical micrometastatic stage within the liver.
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Background
During the earliest stages of the hepatic metastasis proc-
ess, microvascular arrest and residency of disseminated
cancer cells results in the generation of small subclinical
foci of reversible characteristics at liver premetastatic
niches [1]. At this avascular stage, single cancer cells
become multicellular foci. In turn, this demands a func-
tional adaptation of clonogenic cancer cells to the new
microenvironment created by their own three-dimen-
sional (3D) tissue organization, where ambient pressure
and metabolic substrate concentration changes are occur-
ring [2].
Using an experimental hepatic metastasis model [3], we
reported the angiogenesis-stimulating potential activation
in avascular micrometastases prior to hypoxia occurrence,
leading to the intratumoral recruitment of vasculature-
committed stromal cells [3]. This pre-angiogenic event is
connected to hepatic micrometastasis development, but
how the 3D status of cancer cell growth per se contributes
to angiogenic-stimulating potential upregulation in non-
hypoxic micrometastases is unclear.
Spheroids represent a popular in vitro 3D tissue structure
that mimics in vivo tumor tissue organization and micro-
environment [4,5]. Within the spheroid, spatial cancer
cell arrangements and tissue-like features are constituted
that can recapitulate the architecture of the original tumor
[6,7]. Metabolic and signal gradients, 3D-based cell-cell
interactions and communication, and position coordi-
nate-dependent proliferation and gene/protein expres-
sion patterns are also established [5,8,9] which can even
affect the expression of important cell adhesion molecules
[10].
Because a complex tissue-reconstitution program evolves
during compact cancer cell growth in vivo, we hypothe-
sized that angiogenic-stimulating factor production may
be upregulated during in vitro 3D-growth of cancer cells,
even prior to hypoxia occurrence. However, how this is
regulated, which biomarkers are defining the process, and
which functional significance it has in vivo are unclear
questions at the moment.
The purpose of this work was to study proangiogenic fea-
tures in a murine model of colorectal carcinoma cells,
obtained from non-hypoxic 3D-cultured CT26 cancer
cells spheroids, and to evaluate their functional contribu-
tion to hepatic metastasis formation. CT26 spheroids
were generated by the hanging-drop method and used
prior to hypoxic atmosphere development. Proliferation
of cancer cells and recruitment of angiogenic endothelial
cells and myofibroblasts were studied in subcutaneous
tumors and hepatic metastases generated by subcutane-
ous and intrasplenic injection of 3D-and monolayer-cul-
tured CT26 cancer cells.
This study demonstrates that culture of CT26 cancer cells
as multicellular spheroids leads to the expansion of a LFA-
1-expressing cancer cell subpopulation able to further
secrete VEGF in response to soluble ICAM-1, via COX-2-
dependent mechanism in vitro. In addition, 3D growth-
dependent features also endowed cancer cells with an
enhanced angiogenic-stimulating potential in vivo, con-
tributing to subcutaneous and metastatic tumor forma-
tion. These results suggest that the microenvironment
created by the 3D-growth of cancer cells is contributing to
the transition from avascular to vascular stages during
hepatic colon carcinoma metastasis.
Materials and methods
Cell line and maintenance
Murine colon carcinoma cell line (CT26) was obtained
from American Tissue Culture Collection (ATCC, Manas-
sas, VA). Cells were cultured in endotoxin-free RPMI 1640
medium supplemented with 10% fetal bovine serum
(FBS) and 100 units/ml penicillin and 100 μg/ml strepto-
mycin (all tissue culture reagents were from Sigma-
Aldrich, St Louis, MO). Cultures were maintained at 37°C
in a humidified atmosphere with 5% CO2 and passaged as
described previously [11].
Spheroid culture
CT26 spheroids were generated by the hanging drop
method [12]. Five hundred cancer cells suspended in 40
μl of medium (RPMI with 10% FBS and antibiotics) were
dispensed into each well of a 48-well culture tray. Trays
were then inverted and incubated for 7 days. The number
of cancer cells per spheroid was determined by disruption
of individual 3D-tissue structures with PBS-EDTA (4 mM,
10 min) and cell counting using a Neubauer chamber.
Same procedure was used prior to in vitro cancer cell adhe-
sion assays and in vivo cancer cell injections in mice.
Isolation and primary culture of hepatic sinusoidal 
endothelium (HSE) cells
SyngeneicBalb/c mice (male, 6–8 weeks old) were
obtained from Harlan Iberica (Barcelona, Spain). Animal
housing, their care, and experimental conditions were
conducted in conformity with institutional guidelines
that are in compliance with the relevant national and
international laws and policies (EEC Council Directive
86/609, OJ L 358. 1, Dec. 12, 1987; and NIH Guide for
care and use of laboratory animals. NIH publication 85–
23, 1985). HSE cells were separated from these mice,
identified, and cultured as previously described [13].
Briefly, hepatic tissue digestion was performed by sequen-
tial perfusion of pronase and collagenase, and DNase.
Sinusoidal cells were separated in a 17.5% (wt/vol) metri-Journal of Translational Medicine 2008, 6:57 http://www.translational-medicine.com/content/6/1/57
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zamide gradient and incubated in glutaraldehyde-treated
human albumin-coated dishes for 30 minutes, as a selec-
tive adherence step for Kupffer cell depletion. Non-adher-
ent sinusoidal cells were re-plated on type I collagen-
coated 24-well plates, at 1 × 106 cells/ml/well, and 2 hours
later were washed. HSE cell purity of resulting adherent
sinusoidal cells was around 95% as checked by previously
used identification parameters: positive endocytosis
(acetylated low density lipoprotein, ovalbumin); negative
phagocytosis (1 μm latex particles) and CD45 antigen
expression; positive lectin binding-site expression (wheat
germ and viscum album agglutinins); and negative vita-
min A storage (revealed by 328 nm of UV fluorescence).
Cultures of HSE cells were established and maintained in
pyrogen-free RPMI (Sigma-Aldrich, St Louis, MO) supple-
mented with 10% FBS, 100 units/ml penicillin, and 100
μg/ml streptomycin (Sigma-Aldrich, St Louis, MO), at
37°C in a humidified atmosphere with 5% CO2.
Tumor cell adhesion assay to endothelial cells
CT26 cells were labeled with 2',7'-bis-(2-carboxyethyl)-
5,6-carboxyfluorescein-acetoxymethylester (BCECF-AM)
solution (Invitrogen Co, Carsbad, CA). Next, 2 × 105cells/
well CT26 cells grown in monolayer or as spheroids were
disrupted with PBS-EDTA (4 mM, 10 min), stained with
trypan blue for assessment of cell viability and added to
24-well-plate cultured HSE cells and, 30 minutes later,
wells were washed three times with fresh medium. The
number of adhering cells was determined using a quanti-
tative method based on a previously described fluores-
cence measurement system [14].
Hepatic metastasis
SyngeneicBalb/c mice (male, 6–8 weeks old) were
obtained from Harlan Iberica (Barcelona, Spain). Hepatic
metastases were produced through the intrasplenic injec-
tion into anesthetized mice (0.078 mg/kg ketamine and
6.24 mg/kg xilacin) of 1.8 × 105  viable CT26 cells
(obtained from monolayer- or 3D-spheroid-cultures) sus-
pended in 0.1 ml of Hanks' Balanced salt solution
(HBBS). Mice were cervically-dislocated on the 15th day
after the injection of cancer cells and livers were removed.
Livers were fixed by immersion in Zinc solution for 24
hours at room temperature and, then, paraffin-embed-
ded. A minimum of nine 4-μm thick tissue sections of
liver (three groups, separated 1 mm) were stained with
H&E. An integrated image analysis system (Olympus
Microimage 4.0 capture kit) connected to an Olympus
BX51TF microscope was used to quantify the number,
average diameter, and position coordinates of metastases.
Percentage of liver volume occupied by metastases and
metastases density (foci number/100 mm3) were also
determined [14].
Immuno-histochemistry
3D-spheroids of various diameters were fixed in 4% para-
formaldehide solution and paraffin-embedded, or OCT-
embedded and frozen in liquid nitrogen. On the other
hand, zinc-fixed livers and primary tumors from subcuta-
neously-injected mice were also paraffin-embedded. Four
micron-thick paraffin sections were obtained from both
spheroids and tissue samples and were reacted with 1:50
dilutions of rabbit anti-mouse alpha-smooth muscle actin
monoclonal antibody (ASMA) (Zymed, San Francisco,
CA), rat anti-mouse CD31 monoclonal antibody (Becton
Dickinson, Madrid, Spain), or rat-anti-mouse LFA-1 mon-
oclonal antibody (Acris Antibodies, Hiddenhousen, Ger-
many), or with 1:25 dilutions of rat anti-mouse Ki67
(Dako, Denmark). Their appropriate secondary antibod-
ies were anti-rabbit antibody (dilution 1:100, Dako, Den-
mark) and rabbit anti-rat antibody (dilution 1:100, Dako,
Denmark), respectively. Immuno-labeled cells were
detected with an avidin-biotin-phosphatase kit
(Vectastain ABC-AP kit, Vector laboratories, Burlingame,
CA) according to manufacturer's instructions. Sections
were analyzed by quantitative image analysis to deter-
mine the number of Ki67-expressing CT26 cells, and the
intrametastatic densities of ASMA-expressing cells and
CD31-positive capillary cross-sections, as previously
described [15,16].
Cell migration assay
Endothelial cell migration was analyzed with a modified
Boyden chamber, as previously described [3]. HSE cells
(2.5 × 105) were incubated on 0.01% type I collagen-
coated inserts with 8 μm-pores and placed on top of 2 cm2
wells (Becton Dickinson, Madrid, Spain) containing
RPMI or conditioned media from either monolayer-or
3D-cultured CT26 cells. After 48 hours, migrated cells
were stained with H&E and counted in ×40 high-power
fields per membrane.
Conditioned media from CT26 cancer cells were prepared
as follows: 5 × 106monolayer-cultured CT26 cancer cells
and 143 spheroids on the 7th day of culture (assuming
that one single spheroid has 35,000 cells) were incubated
in 10 ml of serum-free RPMI 1640 medium, in a 75-cm2T-
flask, for 12 hours. Supernatants were then collected, 25%
fresh serum-free medium supplemented, and 0.22 μm-fil-
tered prior to being used.
Measurement of VEGF concentration
VEGF concentration was measured using an ELISA kit
based on specific murine VEGF monoclonal antibody as
suggested by the manufacturer (R&D Systems, Abingdon,
UK). Tested supernatants were obtained on the 18th hour
of incubation of monolayer- and 3D-spheroid-cultured
CT26 cells. For both culture conditions, the concentration
of VEGF was expressed as a function of the total numberJournal of Translational Medicine 2008, 6:57 http://www.translational-medicine.com/content/6/1/57
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of cultured cells. In some experiments, CT26 cells received
1 μg/ml celecoxib (kindly supplied by Jaime Masferrer,
Pfizer, Chesterfield, MO) 30 minutes prior to CT26 treat-
ment with 200 ng/ml recombinant human soluble ICAM-
1 (R&D Systems, Abingdon, UK).
Subcutaneous injection of spheroid- and monolayer-
cultured CT26 cells
Balb/c mice received one single subcutaneous injection
(using 16 G-syringe) of 0.1 ml serum-free culture medium
containing either one CT26 cell spheroid- or an equiva-
lent number of monolayer-cultured CT26 cells (around
35,000 cells for 7-day cultured spheroids). Primary
tumors were removed on day 19th after tumor cell injec-
tion and fixed in Zinc solution for immuno-histochemical
analysis of CD31-expressing neoangiogenic tracts using
an integrated image analysis system (Olympus Micro
image 4.0 capture kit) connected to an Olympus BX51TF
microscope.
Flow cytometric analysis
CT26 cells were first incubated for 30 min at 4°C with 1
μg/106 cells of rat anti-mouse LFA-1 antibody (Acris Anti-
bodies, Hiddenhousen, Germany) followed by conju-
gated alexa-IgG2a anti-rat antibody labeling (Invitrogen
Co, Carsbad, CA). Cells were then analyzed by flow
cytometry using a FACS Vantage SE flow cytometer (Bec-
ton Dickinson, Madrid, Spain) by using a wavelength
analysis (green: 530 nm) after excitation with 488-nm
light. Dead cells (<10%) were excluded from the analysis
using Viaprobe (Becton Dickinson, Spain).
Statistical Analyses
Data were expressed as means ± SD. Statistical analysis
was performed by SPPS statistical software for Microsoft
Windows, release 6.0 (Professional Statistic, Chicago, IL).
Homogeneity of the variance was tested using the Levene
test. If the variances were homogeneous, data were ana-
lyzed by using one-way ANOVA test with Bonferroni's cor-
rection analysis for multiple comparisons when more
than two groups were analyzed. For data sets with non-
homogeneous variances, ANOVA test with Tam-
hane'sposthoc was applied. Individual comparisons were
made with Student's two-tailed, unpaired t test (program
Statview 512; Abacus Concepts, Inc., for Macintosh). The
criterion for significance was p < 0.01 for all comparisons.
Results
3D-cultured CT26 cancer cell spheroids
Well-rounded compact 3D-spheroids with a homogene-
ous size distribution were formed in CT26 cancer cell-con-
taining drops suspended from the inverted surface of 48-
well microtiter plates. The efficiency level was nearly
100% –i.e., one spheroid per drop and well–, which is in
contrast to the low-efficient 3D-growth capability of other
cancer cell lines [12]. CT26 spheroids exhibited a highly
organized 3D-tissue-like structure where aggregated can-
cer cells evidenced high proliferation activity until day 7,
when the plateau phase of the growth curve was reached
by CT26 spheroids, while the percentage of Ki67-express-
ing cells markedly decreased (Figure 1). The absence of
pimonidazole staining in 7-day cultured CT26 spheroids
suggests that CT26 spheroids were not affected by hypoxia
at this stage of in vitro growth (data not shown). However,
the concentration of VEGF significantly (P < 0.01)
increased in the supernatant of 3D-cultured CT26 cell
spheroids compared to the level in monolayer-cultured
CT26 cells (Figure 2A). This was particularly visible in the
supernatants obtained on the 7th  day of spheroidal
growth, when VEGF secretion increased by 2-fold, and led
to a significant (p < 0.01) increase by 2-fold in the migra-
tion of primary cultured HSE cells, as compared to the
migration induced by the conditioned medium from an
equivalent number of monolayer-cultured cells (Figure
2B).
As shown by flow cytometry, integrin LFA-1-expressing
cell fraction also increased by 3-fold in CT26 cancer cells
obtained from spheroids (Figure 2C). Immuno-histo-
chemical detection of LFA-1 confirmed that a majority of
spheroid-cultured CT26 cells expressed the integrin, both
at the peripheral and internal areas of the spheroid (Figure
2E–F). Consistent with this feature, the percentage of
CT26 cell adhesion to primary cultured HSE cells signifi-
cantly (p < 0.01) increased by 6-fold in 3D-spheroid-cul-
tured CT26 cells compared to monolayer-cultured cells;
and the addition of 1 μg/ml anti-murine LFA-1 antibody
completely abrogated the adhesion of 3D-spheroid-cul-
tured CT26 cells, but not of monolayer-cultured cells, to
HSE cells (Figure 2D). Moreover, the majority of smallest
avascular CT26 hepatic micrometastases (50–300 μm in
diameter) of non-hypoxic character, and that did not
extend beyond hepatic lobule limits, were already popu-
lated by LFA-1 integrin-expressing CT26 cells (Figure 2G).
3D culture-dependent LFA-1 expression accounts for 
soluble ICAM-1-mediated VEGF secretion by CT26 cells via 
COX-2-dependent mechanism
In a preliminary study we reported that soluble ICAM-1
increases by two-fold in the supernatant of tumor-acti-
vated HSE cells and that, in turn, soluble ICAM-1
increases CT26 cell secretion of VEGF [16]. Herein, both
monolayer- and spheroid-cultured CT26 cells received
200 ng/ml recombinant human soluble ICAM-1 for 18
hours and VEGF concentration was determined by ELISA
in their supernatants. In these conditions, VEGF secretion
potential further increased by 30% and 90% in monol-
ayer- and 3D-spheroid-cultured CT26 cells, respectively,
given soluble ICAM-1 (Figure 3A). This remarkable VEGF
secretion-stimulating activity of soluble ICAM-1 on 3D-Journal of Translational Medicine 2008, 6:57 http://www.translational-medicine.com/content/6/1/57
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spheroid cultured CT26 cells was consistent with LFA-1-
expressing cell number augmentation by 3-fold in 3D-cul-
tured cells compared to monolayer-cultured cells shown
in Figure 2A. Because COX-2 contributes to colon carci-
noma cell production of VEGF [17], in some experiments,
both untreated and soluble ICAM-1-treated monolayer-
and 3D-cultured CT26 cells received 1 μg/ml COX-2
inhibitor Celecoxib for 18 hours. VEGF levels did not sig-
nificantly change in basal condition-cultured CT26 from
both 3D-spheroid and monolayer cultures. However,
Celecoxib completely abrogated VEGF secretion induced
by soluble ICAM-1 on both monolayer- and spheroid-cul-
tured CT26 cells, indicating that VEGF secretion-stimulat-
ing activity of soluble ICAM-1 was COX-2-dependent
(Figures 3A and 3B).
3D-culture-dependent angiogenic potential activation 
enhances hepatic colonization ability of CT26 cancer cells
Nineteen days after subcutaneous injection of monolayer-
and 3D-cultured CT26 cells, the number of CD31-express-
ing cells was determined in developed tumors. As shown
in Figure 4, a marked recruitment of angiogenic cells
occurred at the periphery of subcutaneous tumors gener-
ated by CT26 cells derived from both in vitro growth con-
ditions. However, only those tumors produced by 3D-
cultured CT26 cells were efficiently neovascularized and
had angiogenic tracts in the deepest areas of the tumor.
Overall, CD31-expressing cell densities per unit area were
1.89 ± 0.56 and 0.66 ± 0.25 in tumors from 3D- and mon-
olayer-cultured CT26 cells, respectively (n = 15 mice from
3 independent experiments having 5 mice per group; dif-
Growth stages of 3D-cultured CT26 colon cancer spheroid by the hanging-drop method Figure 1
Growth stages of 3D-cultured CT26 colon cancer spheroid by the hanging-drop method. Five hundred suspension 
cancer cells were dispensed into each well of a 48-well culture tray. Trays were then inverted and incubated during 12 days. 
Spheroids were collected on days 3, 5, 7 and 12 and processed for cell counting, spheroid diameter determination and immu-
nohistochemical detection of Ki67-expressing cells. Scale bar: 100 μm.
3rd day 5th day 7th day 12th day
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(A) VEGF secretion by cultured CT26 cells Figure 2 (see previous page)
(A) VEGF secretion by cultured CT26 cells. Supernatants were obtained on the 18th hour of incubation of CT26 cells, 
and the concentration of VEGF was determined by ELISA. (B) Hepatic sinusoidal endothelium (HSE) cell migration in response 
to conditioned media from CT26 cells. Primary cultured HSE cells were incubated for 48 hours with CT26 cell-conditioned 
media and endothelial cell migration was assayed across type-I collagen-coated inserts. (C) Flow cytometric study on LFA-1 
expression. CT26 cells were incubated for 30 minutes at 4°C with 1 μg/106 cells of rat anti-mouse LFA-1 antibody followed by 
conjugated alexa-IgG2a anti-rat antibody labeling. (D) Adhesion assays of CT26 cells to HSE cells. CT26 cells received 1μg/ml 
anti-murine LFA-1 antibodies 30 min prior to the adhesion assay. All data from A-to-D studies represent average values ± SD 
from 3 different experiments (n = 18). Statistical significance: (*) p < 0.01 as compared to monolayer-cultured CT26 cancer 
cells; (**) p < 0.01 as compared to untreated CT26 cancer cells. (E-F) Inmunofluorescence pictures on LFA-1 expression 
(green staining) by 3D-spheroid-cultured CT26 cells and (G) a vascular hepatic micrometastases (arrows) on the 7th day after 
intrasplenic injection of monolayer-cultured CT26 cells. Red staining corresponds to ASMA-expressing fibroblasts around a 
terminal portal venule and some sinusoids. Scale bar: 20 μm.
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ferences were statistically significant by the Student's two-
tailed, unpaired t test, p < 0.01).
Intrasplenic injection of CT26 cancer cells revealed that
hepatic metastasis development significantly (P < 0.01)
increased in mice receiving 3D-spheroid-cultured CT26
cells, as compared to mice given monolayer-cultured
CT26 cells (Figure 5A and Figure 5B). This was particularly
evident when comparing the metastasis volume indices
produced by well-established metastases of medium and
big size. Consistent with the proangiogenic activation of
spheroid-growing CT26 cancer cells, both endothelial cell
(as CD31-expressing cells) and alpha-smooth muscle
actin (SMA)-expressing cell numbers significantly (p <
0.01) increased in metastatic nodules produced by 3D-
cultured CT26 cells as compared to those developed by
monolayer-cultured CT26 cells (Figures 5C–F). As previ-
ously described[3], intrametastatic SMA cells were mainly
hepatic sinusoidal stellate cell-derived myofibroblasts act-
ing as vascular coverage pericytes of neoangiogenic tumor
vessels. Moreover, consistent with the metastatic volume
augmentation evidenced in the livers of 3D-spheroid-cul-
tured CT26 cell-injected mice, the average proliferating
cell number per unit area of metastatic tissue also signifi-
cantly increased by 35%, in 3D-spheroid-cultured CT26
cell-injected mice, as detected by immuno-histochemistry
using anti-ki67 antibodies (Figures 5G–H).
Discussion
The results of this study demonstrate that in vitro and in
vivo 3D-growth status per se activates the proangiogenic
phenotype of CT26 cancer cells, prior to hypoxia occur-
rence. Acquisition of this important feature of the cancer
phenotype was evidenced by the significant increase of
VEGF secretion when CT26 cancer cells were cultured as
3D-spheroids, and by the remarkable angiogenic tract-for-
mation activity provided by 3D-cultured CT26 cells at
both subcutaneous tumors and hepatic metastases. This
mechanism was contributed by integrin LFA-1, which sig-
nificantly increased in both 3D-cultured CT26 cells and
non-hypoxic avascular CT26 hepatic micrometastases. In
turn, over-expression of this integrin enhanced the adhe-
sion of CT26 to ICAM-1-expressing angiogenic hepatic
myofibroblasts and endothelial cells; and endowed CT26
cells with the capability to further increase VEGF secre-
tion, via COX-2, in response to soluble ICAM-1 (Figure
3B), a factor increasing both in the hepatic blood after
cancer cell infiltration, and in the peripheral blood of
patients affected by numerous cancer types [18,19].
Neoplastic tissues contain a complex spatial organization
of growing cancer cells that is missed in traditional mon-
olayer culture systems. Most of structural and functional
features of cancer cells are affected by their position coor-
dinates and ambient pressure within tumor tissue, sug-
gesting that biological and therapeutic studies based on
two-dimensional cancer cell cultures may lead to inaccu-
rate conclusions that cannot be easily used for transla-
tional research and clinical validations. Multicellular
spheroids mimic the microenvironment within avascular
tumors, and may represent a simple approach to study
inducibility of prometastatic factors. Several studies have
reported that cancer cell growth as spheroids involves an
altered expression profile of cell adhesion molecules [10],
and even increased expression of VEGF [20,21]. However,
how this is regulated and which functional significance it
has in vivo are, at the moment, unclear questions.
According to our results, CT26 cells grown either at
micrometastatic niches in vivo, or as 3D-cancer cell sphe-
roids  in vitro, markedly increased LFA-1-expressing cell
number. Previous studies have already reported that
expression of this integrin contributes to hepatic invasion
and metastasis of lymphoma, leukemia and breast cancer
cells [22,23]; that LFA-1 blockade using specific antibod-
ies can inhibit the hepatic colonization process [24]; and
that ICAM-1 deficient mice can prevent post-homing
events contributing to the hepatic colonization of T-lym-
phoma cells [25]. Moreover, HT-29 colon cancer cells
grown as spheroids increased CD44 expression [10] and
stimulation of this specific cell line by CD44-ligand
hyaluronan can induce integrin-mediated adhesion and
migration via LFA-1 up-regulation [23]. In the present
study, the adhesion of 3D-cultured CT26 cells to primary
cultured hepatic sinusoidal endothelial cells increased by
6-fold, and to proangiogenic hepatic stellate cell-derived
myofibroblasts, by 2-fold (preliminary data not shown),
compared to monolayer-cultured cells. In both cases, this
occurred via LFA-1-dependent mechanism as shown by
specific anti-LFA-1 blockade. Unlike other microvessels,
hepatic sinusoids exhibit elevated base-line expression of
ICAM-1 under normal physiological conditions [26,27],
suggesting that cancer cell expression ofLFA-1 contributes
to retention and seeding of liver-infiltrating colon carci-
noma cells. Moreover, activated hepatic myofibroblasts
also express ICAM-1 [28] and, therefore, our results sug-
gest that LFA-1 expression may facilitate the functional
interaction of cancer cells with ICAM-1-expressing myofi-
broblasts recruited into smallest micrometastases during
early stromagenesis occurring prior to angiogenesis. This
stromal-tumor cell interaction may further contribute to
VEGF secretion from3D-growing cancer cells within avas-
cular micrometastases.
Our study also shows that recombinant soluble ICAM-1
induced VEGF production from LFA-1-expressing colon
cancer cells. This mechanism accounted for 30% of VEGF
production from monolayer-cultured CT26 cells, but it
augmented VEGF production by 3-fold in 3D-cultured
cells. Moreover, there was a strict correlation betweenJournal of Translational Medicine 2008, 6:57 http://www.translational-medicine.com/content/6/1/57
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(A) Effect of COX-2 inhibition on VEGF secretion by recombinant soluble ICAM-1-treated CT26 cells Figure 3
(A) Effect of COX-2 inhibition on VEGF secretion by recombinant soluble ICAM-1-treated CT26 cells. In some 
experiments, CT26 cells received 1 μg/ml of celecoxib 30 min prior to treatment with sICAM-1. VEGF concentration was 
measured with ELISA in 18-hour supernatants obtained in serum-free culture conditions. Data represent the mean ± SD of 
three separate experiments, each in six replicates (n = 18). Differences in VEGF secretion with respect to untreated (*) and 
sICAM-1-treated (**) monolayer-cultured cells, and with respect to untreated (#) and sICAM-treated-(##) 3D-spheroid-cul-
tured CT26-CC cells were statistically significant (p < 0.01) by ANOVA and Bonferroni's post-hoc test. (B) Interaction of 
tumor LFA-1-expressing CT26 cancer cells with hepatic sinusoidal endothelial cells, via membrane and soluble ICAM-1, induces 
tumor VEGF overproduction via COX-2 pathway. Next, VEGF induces endothelial cell migration towards a vascular microme-
tastasis promoting angiogenesis.
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LFA-1 expression and VEGF production levels in CT26
colon carcinoma cells activated by soluble ICAM-1. In the
liver, metastatic cancer cells that have survived to the cyto-
toxic environment of the microvasculature start to grow in
tight association to hepatic sinusoidal endothelial cells
and stellate cell-derived myofibroblasts [3]. Both sinusoi-
dal cell types express and secrete ICAM-1 induced by
tumor-derived factors. Soluble ICAM-1 level is also signif-
icantly higher in patients with liver metastasis than in
those without liver metastasis [18,19]. Therefore, upregu-
lation of LFA-1 expression on cancer cells at this early
stage of the hepatic metastasis process may contribute to
VEGF production by metastatic cells interacting with liver-
derived ICAM-1. However, this mechanism may require
the LFA-1-stimulating microenvironment created by the
early 3D-growth of cancer cells preceding angiogenesis in
the pathogenic cascade of the hepatic metastasis process.
Consistent with this mechanism, it has been reported that
both tumor- and host-derived soluble ICAM-1 promote
Angiogenic potential of cancer cells from monolayer and 3D-cultured CT26 cancer cells Figure 4
Angiogenic potential of cancer cells from monolayer and 3D-cultured CT26 cancer cells. One 3D-spheroid per 
mouse with a concentration of around 35,000 cells per spheroid was subcutaneously injected in 15 mice (three independent 
experiments; 5 mice/experiment). The same cancer cell number from monolayer-cultured CT26 was subcutaneously-injected 
into control mice. Subcutaneous tumors were removed on day 19th after tumor cell injection and processed for CD31 immu-
nostaining. CD31-expression was enhanced by image analysis and CD31-expressing cell density per unit area was determined.
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Monolayer- and 3D-cultured CT26 cancer cells were intrasplenically injected into Balb/c mice (n = 10 per group) Figure 5
Monolayer- and 3D-cultured CT26 cancer cells were intrasplenically injected into Balb/c mice (n = 10 per 
group). (A) Hepatic metastasis volume fractions are represented according to metastasis size classes (------: 3D-spheroid-cul-
tured cells;__________: monolayer-cultured cells). (B) Total hepatic metastasis volumes (as average values) from each mouse 
group. (C) ASMA-expressing cell number, (E) CD31-expressing endothelial cell number, and (G) Ki67-expressing cancer cell 
number per unit area of metastasis (0.29 mm2) were determined by immunohistochemistry in 3 tissue sections per liver, from 
10 livers per group. Differences in average values ± SE were statistically significant with respect to mice injected with monol-
ayer cultured-CT26 cells (p < 0.01) according to the ANOVA and Tamhane's post hoc test. Inmunohistochemical staining of 
ASMA- (D), CD31- (F) and Ki67- (H) expressing cells in hepatic metastasis. Bar: 200 μm.
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angiogenic activity [29] and support tumor growth [30].
However, our results show for first time that soluble
ICAM-1 can directly confer angiogenic-stimulating prop-
erties to LFA-1-expressing colon carcinoma cells grown in
the hepatic microenvironment. Our results also reveal
that the angiogenesis-stimulating potential induced by
soluble ICAM-1 on LFA-1-expressing colon carcinoma
cells was regulated by cyclooxygenase-2. Upregulation of
COX-2 expression has a frequent occurrence in a variety of
different tumors including colorectal carcinoma [31,32]
and it has been associated to tumor angiogenesis [33].
Because COX-2 accounted for 30% of VEGF from monol-
ayer-cultured CT26 cells, and for 65% of VEGF from 3D-
cultured CT26 cells, our results suggest that tumor-derived
VEGF is mainly COX-2-dependent during 3D cancer cell
growth at the avascular micrometastasis stage (Figure 3B).
Finally, based on a comparative proteomic analysis of
cytosolic samples from monolayer- and 3D-cultured
CT26 cells we have detected the specific over-expression
by 3D-cultured cells of a selected group of biomarker pro-
teins including: 60S acidic ribosomal protein-1, ferritin
heavy chain, phosphoglycerate kinase-1, estrogen-related
receptor alpha, vimentin and 14-3-3 epsilon (data not
shown). Because these proteins have already been associ-
ated to mechanisms of cancer progression and tumor ang-
iogenesis, new studies are now in progress to analyze the
hepatic pro-metastatic role of this selected ensemble of
proteins associated to the 3D-growth of CT26 colorectal
carcinoma cells.
Conclusion
This study demonstrates that culture of CT26 cancer cells
as multicellular spheroids leads to the expression of a dis-
tinct proangiogenic protein profile, including the specific
expansion of a LFA-1-expressing cancer cell subpopula-
tion able to interact with ICAM-1-expressing hepatic
endothelial cells and myofibroblasts, and to increase
VEGF secretion in response to membrane and soluble
ICAM-1, via COX-2-dependent mechanism (Figure 3B).
In vivo, CT26 cells also expressed LFA-1 integrin since
their earliest 3D-growth of non-hypoxic avascular
micrometastasis in the liver, suggesting that 3D-growth-
dependent features endowed colorectal cancer cells with
an enhanced capability to produce VEGF in response to
ICAM-1 provided by tumor-activated hepatic cells. There-
fore, the microenvironment created by the 3D-growth of
cancer cells may per se promote the transition from avas-
cular to vascular stage during hepatic colon carcinoma
metastasis.
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